These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 7095998)
21. Adjuvant preoperative and postoperative immunochemotherapy for mammary adenocarcinoma in rats. Sparks FC; O'Connell TX; Lee YT Surg Forum; 1973; 24():118-21. PubMed ID: 4618633 [No Abstract] [Full Text] [Related]
22. Immunologic competence of regional lymph nodes in patients with mammary cancer. Humphrey LJ; Barker C; Bokesch C; Fetter D; Amerson JR; Boehm OR Ann Surg; 1971 Sep; 174(3):383-91. PubMed ID: 5111281 [No Abstract] [Full Text] [Related]
23. Influence of immunotherapeutic agents on the progression of spontaneously arising, metastasizing rat mammary adenocarcinomas of varying immunogenicities. Greager JA; Baldwin RW Cancer Res; 1978 Jan; 38(1):69-73. PubMed ID: 618584 [No Abstract] [Full Text] [Related]
25. Increased immunogenicity of a spontaneous variant clone of the 13762A rat mammary adenocarcinoma. Kreider JW; Bartlett GL J Natl Cancer Inst; 1985 Jul; 75(1):141-9. PubMed ID: 3859687 [TBL] [Abstract][Full Text] [Related]
26. Correlation between tumor-specific systemic and in situ immunity as manifested by the delayed hypersensitivity response. Radov LA; Haskill JS; Korn JH; Fett JW J Natl Cancer Inst; 1979 Jan; 62(1):103-8. PubMed ID: 281564 [No Abstract] [Full Text] [Related]
27. Antitumor IgE adjuvanticity: key role of Fc epsilon RI. Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979 [TBL] [Abstract][Full Text] [Related]
28. InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Zhou F; Li X; Naylor MF; Hode T; Nordquist RE; Alleruzzo L; Raker J; Lam SS; Du N; Shi L; Wang X; Chen WR Cancer Lett; 2015 Apr; 359(2):169-77. PubMed ID: 25633839 [TBL] [Abstract][Full Text] [Related]
29. Immunological relatedness of a murine mammary tumor-associated antigen and human breast cancer. Chattopadhyay J; Chattopadhyay U; Chowdhury JR Gan; 1984 Apr; 75(4):342-8. PubMed ID: 6329885 [TBL] [Abstract][Full Text] [Related]
30. Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant. Chen WR; Korbelik M; Bartels KE; Liu H; Sun J; Nordquist RE Photochem Photobiol; 2005; 81(1):190-5. PubMed ID: 15535737 [TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of monoclonal antibodies (epi-1 and myo-1) derived from human breast cancer against rat mammary tumors. Yamamoto H; Imai S; Yamamoto I Exp Toxicol Pathol; 1992 Sep; 44(5):235-8. PubMed ID: 1446159 [TBL] [Abstract][Full Text] [Related]
32. [Trials of (poly A. poly U) adjuvant immunotherapy in breast cancer treatment]. Lacour J; Lacour F; Spira A; Delage G; Michelson AM Bull Cancer; 1974; 61(2):275-80. PubMed ID: 4465011 [No Abstract] [Full Text] [Related]
33. Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Further experimental studies on chessboard vaccination in canine mammary tumors. Sedlacek HH; Hagmayer G; Seiler FR Cancer Immunol Immunother; 1986; 23(3):192-9. PubMed ID: 3791304 [TBL] [Abstract][Full Text] [Related]
34. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats. Chen WR; Liu H; Ritchey JW; Bartels KE; Lucroy MD; Nordquist RE Cancer Res; 2002 Aug; 62(15):4295-9. PubMed ID: 12154032 [TBL] [Abstract][Full Text] [Related]
35. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors. Ben-Hur H; Kossoy G; Zandbank J; Zusman I Int J Mol Med; 2002 Apr; 9(4):425-30. PubMed ID: 11891540 [TBL] [Abstract][Full Text] [Related]
36. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice. Wolmark N; Fisher B Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513 [No Abstract] [Full Text] [Related]
37. Regression of cutaneous neoplasms following delayed-type hypersensitivity challenge reactions to microbial antigens or lymphokines. Holtermann OA; Papermaster B; Rosner D; Milgrom H; Klein E J Med; 1975; 6(2):157-68. PubMed ID: 1099159 [TBL] [Abstract][Full Text] [Related]
38. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438 [TBL] [Abstract][Full Text] [Related]
39. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects. Minev BR; Guo F; Gueorguieva I; Kaiser HE In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883 [TBL] [Abstract][Full Text] [Related]